Deutsche Bank Aktiengesellschaft Raises Sanofi (NASDAQ:SNY) Price Target to €90.00

Posted by MarketBeat News on Aug 1st, 2022

Sanofi (NASDAQ:SNY – Get Rating) had its target price boosted by Deutsche Bank Aktiengesellschaft from €85.00 ($86.73) to €90.00 ($91.84) in a research note published on Friday morning, The Fly reports. They currently have a sell rating on the stock.

Several other equities analysts have also recently weighed in on the stock. Guggenheim lifted their price objective on shares of Sanofi from €121.00 ($123.47) to €127.00 ($129.59) in a research report on Monday, May 2nd. Morgan Stanley lifted their target price on shares of Sanofi from €110.00 ($112.24) to €112.00 ($114.29) in a research note on Friday, April 22nd. Credit Suisse Group lifted their target price on shares of Sanofi from €105.00 ($107.14) to €110.00 ($112.24) and gave the company an outperform rating in a research note on Friday, July 22nd. Barclays lifted their target price on shares of Sanofi from €90.00 ($91.84) to €105.00 ($107.14) in a research note on Thursday, April 14th. Finally, SVB Leerink assumed coverage on shares of Sanofi in a research note on Monday, May 23rd. They set an outperform rating for the company. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $110.50.

Sanofi Trading Down 2.4 %

NASDAQ SNY opened at $49.70 on Friday. Sanofi has a twelve month low of $46.92 and a twelve month high of $58.10. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.03 and a current ratio of 1.44. The stock has a market cap of $125.78 billion, a price-to-earnings ratio of 16.08, a PEG ratio of 1.24 and a beta of 0.50. The firm’s 50 day moving average price is $51.45 and its two-hundred day moving average price is $52.19.

Sanofi (NASDAQ:SNY – Get Rating) last posted its quarterly earnings data on Thursday, April 28th. The company reported $1.09 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.15. Sanofi had a net margin of 17.15% and a return on equity of 25.34%. The firm had revenue of $10.85 billion for the quarter, compared to analysts’ expectations of $10.33 billion. Equities analysts anticipate that Sanofi will post 4.06 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SNY. Boston Partners raised its holdings in Sanofi by 62.3% in the 1st quarter. Boston Partners now owns 11,272,368 shares of the company’s stock worth $580,302,000 after acquiring an additional 4,328,799 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Sanofi by 276.1% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock worth $172,611,000 after acquiring an additional 2,468,271 shares during the period. Bank of America Corp DE raised its holdings in Sanofi by 14.4% in the 1st quarter. Bank of America Corp DE now owns 12,051,921 shares of the company’s stock worth $618,746,000 after acquiring an additional 1,512,434 shares during the period. Goldman Sachs Group Inc. raised its holdings in Sanofi by 29.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,227,680 shares of the company’s stock worth $111,607,000 after acquiring an additional 506,752 shares during the period. Finally, Aaron Wealth Advisors LLC increased its holdings in shares of Sanofi by 5,487.1% during the 1st quarter. Aaron Wealth Advisors LLC now owns 415,289 shares of the company’s stock worth $8,089,000 after purchasing an additional 407,856 shares during the period. Institutional investors own 12.82% of the company’s stock.

Sanofi Company Profile

(Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.